24/7 Wall Street
09 Jul 2026, 15:35 UTC · 16w ago
Impact · against what's priced in
The article provides a bullish catalyst for the biotech sector based on a regulatory shift at the FDA that should unlock a wave of M&A. While Eli Lilly and Vertex are confirming existing aggressive acquisition strategies, Alnylam presents a specific valuation dislocation that may attract strategic buyers.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
A leadership change at the FDA has removed a dealmaking freeze, which is expected to lead to a flood of biotech acquisitions.
More positive than 99% of claims this week
Eli Lilly completed four acquisitions in Q1 2026, funded by strong growth in its obesity and diabetes franchise.
Continue reading
5 related stories
Despite a 21% YTD stock decline, Alnylam shows massive fundamental strength with 187% revenue growth and projected 2026 product revenue up to $5.3 billion, making it a prime takeover target.
Read from the article alone
No priced-in read yet
Eli Lilly is leveraging massive growth in its obesity franchise (Mounjaro 125%, Zepbound 80%) to fund an aggressive acquisition pace, completing four deals in Q1 2026 alone.
Read from the article alone
No priced-in read yet
Vertex is successfully using tuck-in M&A, such as the $4.9 billion Alpine Immune Sciences deal, to diversify its franchise into nephrology.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 92% of claims this week
Alnylam Pharmaceuticals' stock has fallen 21% YTD despite 187% revenue growth, creating a valuation dislocation that makes it a likely takeover target.
More positive than 75% of claims this week
The iShares Biotechnology ETF (IBB) has returned over 51% over the past year, signaling strong momentum in the sector.
More positive than 61% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Strong financial growth in obesity and diabetes franchises and an aggressive, successful acquisition strategy.
More positive than 74% of ticker scores this week
Despite stock underperformance, the company shows massive revenue growth and is cited as a highly attractive takeover target.
More positive than 67% of ticker scores this week
Praised as a model for using tuck-in M&A to expand its franchise into new therapeutic areas.
More positive than 63% of ticker scores this week
Positive revenue growth and progress in its obesity program, benefiting from a more favorable FDA deal environment.
More positive than 52% of ticker scores this week
Mentioned as a company traders are watching closely for a potential acquisition.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a historical reference for an analyst's accuracy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
18h ago
More positive than 34% of relationship scores this week
[mutual] Both companies are competing in the obesity treatment market, with Lilly's Zepbound and Amgen's MariTide program.
−51.2%
Price is moving against the score
$158.00 vs $323.50 close before publication (Jul 8) · not market-adjusted
ALNY chart →+16.1%
Price agrees with the score
$1411.35 vs $1215.83 close before publication (Jul 8) · not market-adjusted
LLY chart →+11.0%
Price agrees with the score
$553.15 vs $498.43 close before publication (Jul 8) · not market-adjusted
VRTX chart →
